Lacosamide
Lacosamide is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Lacosamide; Generic name: LACOSAMIDE; Manufacturer: Alembic Pharmaceuticals Inc..
| Brand name | Lacosamide |
|---|---|
| Generic name | LACOSAMIDE |
| Manufacturer | Alembic Pharmaceuticals Inc. |
| Used for | 1 INDICATIONS AND USAGE Lacosamide tablets are indicated for: • Treatment of partial-onset seizures in patients 4 years of age and older (1.1) • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older (1.2) 1.1 Partial-Onset Seizures Lacosamide tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. Additional pediatric use information is approved for UCB, Inc.’s VIMPAT ® (lacosamide) tablets. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. 1.2 Primary Generalized Tonic-Clonic Seizures Lacosamide tablets are indicated |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Adults (17 years and older): o Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily (2.1) o Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily (2.1) o Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily (2.1) • Pediatric Patients 4 years to less than 17 years: The recommended dosage is based |
| Active ingredient(s) | LACOSAMIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07b7b3f2-16a0-4deb-883b-10522676d966 |